StockGuide AI
Track Stocks
EN RU ES
Vaxcyte

Vaxcyte

Price: 45.42

Company and Business Model

Vaxcyte, Inc. is a biotechnology company focused on developing innovative vaccines to address infectious diseases. Its core products include a pipeline of vaccine candidates targeting various pathogens, with a primary emphasis on pneumococcal disease. The company operates within the healthcare sector, primarily generating revenue through research and development activities and potential future product sales.

Investment Profile

The investment profile of Vaxcyte is more aligned with growth investors, given its focus on developing new vaccine technologies and the potential for significant future revenue from successful product launches. The stock may appeal to those with a medium to long-term investment horizon, as the company is still in the development phase. Liquidity is moderate, suitable for investors with basic to advanced experience in the biotech sector.

Official website

Fundamental metrics (experimental)

EPS (TTM) — earnings per share for the last 12 months, $
-6.89 Risk
EPS surprise
-29.7% worse than expected
20d volatility
3.0% stable
FMP / FinFeed data updated: 2026-06-06
Reco: Sell Potential: 30 Risk: 73 Updated: 2026-06-11 05:24
How recommendation works
Why AI thinks so:
Weak fundamentals and negative momentum raise significant concerns.

Track in portfolio

Price chart

AI recommendation Analyst forecast Calendar event Positive signal Negative signal Neutral / update Hold / informational B My buy S My sell
AI recommendation changes
Date Before After Reason
2026-06-03 02:49 Hold Sell scenario_deterioration
2026-05-28 02:54 Sell Hold Weak fundamentals and negative momentum raise concerns.
2026-05-20 02:53 Hold Sell scenario_deterioration
Analyst forecasts
Date Analyst Action Target Price Then
2026-02-25 19:27 BTIG Target Raised — → 89 63.04
2025-11-19 10:23 Leerink Partners Target Raised — → 77 49.53